drugset / Trial / NCT02360852
IBAT Inhibitor A4250 for Cholestatic Pruritus
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability and influence on itching, bile acids and liver enzyme changes in patients with PBC (Primary Biliary Cirrhosis) treated with A4250
Timeline
- Start
- 2015-01
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Odevixibat | Small molecule | 1.5 mg | Oral |
| Subject | Odevixibat | Small molecule | 3 mg | Oral |